Please enable JavaScript in your web browser settings, under the site permissions section to unlock full site functionality. Click here for help.

Article Image - OPKO Health Acquires EirGen Pharma

Posted 28th May 2015

OPKO Health Acquires EirGen Pharma

OPKO Health Acquires EirGen Pharma

Scroll to keep reading

OPKO Health Acquires EirGen Pharma

OPKO Health Acquires EirGen Pharma

View Biography

Paul Heffernan, Legal Adviser OPKO Health

OPKO Health, Inc. is pleased to announce the acquisition of EirGen Pharma, Ltd., a growing, profitable and cash flow positive specialty pharmaceutical company focused on the development and commercial supply of high potency, high barrier to entry, pharmaceutical products for sale in the U.S., Canada, Japan, Australia, most European countries, and more than 40 others around the world.

EirGen, based in Waterford, Ireland, was founded by two former executives of IVAX Pharmaceuticals, Tom Brennan and Patsy Carney. The company, situated in a state of the art high containment research and development, and manufacturing facility, is approved by the FDA, EMEA (European Health Authorities) and the PMDA (Japanese Health Authorities). High potency drugs such as those used for cancer chemotherapy are typically unsuitable for manufacture in normal multi-product facilities due to cross contamination risks.

To date, EirGen and its commercial partners have filed 10 product applications with the FDA and 5 each in Europe and Japan. EirGen has a strong research and development portfolio of over 20 niche, high barrier to entry drugs and, with access to additional capital that OPKO will provide, together with the benefits of Irish government programs to encourage research and development in Ireland, EirGen will rapidly expand its drug portfolio.

“EirGen Pharma is one of the leading developers and suppliers of high potency niche pharmaceutical products in the world,” said Phillip Frost, M.D. OPKO’s Chairman and CEO. “As FineTech, OPKO’s Israeli active pharmaceutical ingredient manufacturing subsidiary, is also focused on high potency drugs, an immediate business synergy is expected. EirGen also offers the significant benefit of potentially being able to manufacture OPKO’s current and future products in our own facilities, which we expect will result in even higher gross margins. The superb management, research and development, manufacturing and product distribution teams, along with state of the art facilities, together, will create an important, tax efficient base of operations for OPKO,” said Dr. Frost.

Categories: M&A, Strategy

You Might Also Like

Lower Profits at Brazil’s Foreign Banks Limit Expansion

16/02/2015Lower Profits at Brazil’s Foreign Banks Limit Expansion

Reduced profits from capital market-related activities to hold back plans for expansion in the country.

ECRI: Leading the Fight Against Cardiovascular Disease

15/12/2025ECRI: Leading the Fight Against Cardiovascular Disease

Named Europe’s Cardiology Research Organisation of the Year 2025, the European Cardiovascular Research Institute (ECRI) is advancing investigator-led clinical trials like IVUS-CHIP, OPTIMAL, FAST III and ZEPHYR to transform cardiovascular care across Europe

Centum Acquisition of a Controlling Stake in K-Rep Bank

01/02/2015Centum Acquisition of a Controlling Stake in K-Rep Bank

Centum, the East African investment firm, announced the acquisition of a controlling stake in Kenyan bank K-REP Bank Limited.

Looking to the Future: The Forecasted Trends of Business Analytics

29/01/2024Looking to the Future: The Forecasted Trends of Business Analytics

It can sometimes be difficult to predict what might come next. For example, consider the weather model a local meteorological service may provide to communities – while it may be possible to determine a forecast for seven days to a high degree of accurac

One in Three Enterprise Devices Lack Encryption as Shadow AI Runs Wild

01/10/2025One in Three Enterprise Devices Lack Encryption as Shadow AI Runs Wild

Over one in three (35)% of enterprise PCs are not encrypted, despite standard security policies, amid millions of visits to generative AI platforms such as DeepSeek, often without formal approval or monitoring.

First Quarter Update – KBS Corporate

17/05/2016First Quarter Update – KBS Corporate

KBS Corporate is recognised as one of the UK’s leading providers of company sales services, offering complete project management and consultancy services to shareholders and owner managers who are considering an exit strategy.

06/05/2022Post Haste!

The team at MailAmericas are a vital link for those in Latin America and have expanded across borders. This growth has seen them named Best Cross-Border Logistics Solutions Provider 2021 – Americas in Acquisition International’s Global Excellence Awards.

The Global Face of Fraud: Mitigating Fraud Risks When Expanding Internationally

13/11/2023The Global Face of Fraud: Mitigating Fraud Risks When Expanding Internationally

Global expansion is the way forward for businesses looking to upscale in 2023 and beyond. The past few years have laid the foundation for international expansion, and now more and more merchants are embracing the opportunities.

Broadstone Secures A Further £1.5m To Fuel Expansion Following Major Contract Wins

30/01/2020Broadstone Secures A Further £1.5m To Fuel Expansion Following Major Contract Wins

Existing investors continue to back company's aim to transform flexible workforces in regulated industries.

View More Articles

Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

MORE BRANDS